Company Name
Aurinia Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
CA05156V1022
CIK:
0001600620
CUSIP:
05156V102
Currency:
USD
Full Time Employees:
128
Phone:
250 744 2487
Website:
https://www.auriniapharma.com
Fiscal Year End:
December
IPO Date:
Jan 26, 1999
Description:
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Address:
#140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6